Kisqali is indicated in combination with:

a non-steroidal aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2

(HER2)-negative locally advanced or metastatic breast cancer, as initial endocrine-based therapy; or fulvestrant for the treatment of men and postmenopausal women with HR-positive, HER2- negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.

 

 


 



Afinitor 2.5, 5 & 10mg are indicated for the:

1. Treatment of patients with SEGA associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not candidates for curative surgical resection.

The effectiveness of AFINITOR is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.

 

2. Treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease. The safety and effectiveness of AFINITOR® in the treatment of patients with carcinoid tumors have not been established.

 

3. Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.

 

4. Treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex

(TSC), not requiring immediate surgery. The effectiveness of AFINITOR in treatment of

renal angiomyolipoma is based on an analysis of durable objective responses in patients

treated for a median of 8.3 months. Further follow-up of patients is required to determine

long-term outcomes.

 

5. Treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy.

6. Treatment of unresectable, locally advanced or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.

×

Medical Information Request

×

Ask Speakers